Given that in PDAC, elevated IL-20 levels correlate with poor prognosis, preclinical studies have demonstrated that neutralization of IL-20 using monoclonal antibodies, such as 7E, inhibits tumor growth, reduces PD-L1 expression, and alleviates cachexia symptoms in mouse models. Here, IL20 is linked to neoplasm.